LUIS CAMINAL MONTERO-rekin lankidetzan egindako argitalpenak (10)

2020

  1. Erratum: Low-density granulocytes and monocytes as biomarkers of cardiovascular risk in systemic lupus erythematosus (Rheumatology (2020) 59 (1752-1764) DOI: 10.1093/rheumatology/keaa016)

    Rheumatology (United Kingdom)

  2. IgM anti-phosphorylcholine antibodies associate with senescent and IL-17+ T cells in SLE patients with a pro-inflammatory lipid profile

    Rheumatology (Oxford, England), Vol. 59, Núm. 2, pp. 407-417

  3. Low-density granulocytes and monocytes as biomarkers of cardiovascular risk in systemic lupus erythematosus

    Rheumatology (Oxford, England), Vol. 59, Núm. 7, pp. 1752-1764

2019

  1. IRF4 and IRGS delineate clinically relevant gene expression signatures in systemic lupus erythematosus and rheumatoid arthritis

    Frontiers in Immunology, Vol. 10, Núm. JAN

2017

  1. Circulating microparticle subpopulations in systemic lupus erythematosus are affected by disease activity

    International Journal of Cardiology, Vol. 236, pp. 138-144

  2. Serum levels of anti-PON1 and anti-HDL antibodies as potential biomarkers of premature atherosclerosis in systemic lupus erythematosus

    Thrombosis and Haemostasis, Vol. 117, Núm. 11, pp. 2194-2206

2016

  1. A pathogenic IFNα, BLyS and IL-17 axis in systemic lupus erythematosus patients

    Scientific Reports, Vol. 6

  2. Senescent profile of angiogenic T cells from systemic lupus erythematosus patients

    Journal of Leukocyte Biology, Vol. 99, Núm. 3, pp. 405-412

2014

  1. Anti-ribosomal P antibodies are associated with elevated circulating IFNα and IL-10 levels in systemic lupus erythematosus patients

    Lupus, Vol. 23, Núm. 14, pp. 1477-1485

  2. Interferon-α-induced B-lymphocyte stimulator expression and mobilization in healthy and systemic lupus erthymatosus monocytes

    Rheumatology (United Kingdom), Vol. 53, Núm. 12, pp. 2249-2258